Aniracetam 72432-10-1

98% up by HPLC, WC, DMF

Product categories

New Products

Product Details

Product Information

Product name	Aniracetam
CAS No.	72432-10-1
Molecular Formula	C12H13NO3
Molecular Weight	219.24
Quality Standard	98% up by HPLC
Appearance	White or off-white crystalline powder

COA

ANALYSIS	SPECIFICATION	RESULTS
Appearance	White or off-white crystalline powder, odorless and a little bitter	Conforms
Melting Point	118-122^。C	120.1-121.9^。C
Absorbance	476-506	492
Chemical Reaction	Generate white precipitate	Conforms
IR Identification	Should comply with the reference spectrum	Comply with the reference spectrum
Related Substances
Individual Impurity	≤0.2%	0.1%
Total Impurities	≤0.5%	0.2%
Residual solvent
Methanol	≤0.3%	ND
Ethanol	≤0.5%	ND
Ethyl Acetate	≤0.5%	ND
Toluene	≤0.089%	ND
Loss on Drying	≤0.5%	0.40%
Residual on Ignition	≤1.0%	0.05%
Heavy metals	≤10ppm	Conforms
Assay	98.0% - 102.0%	101.0%
Microbial Limit
Bacterial count	≤1000cfu/g	<10cfu/g
Mold and Yeast Count	≤100cfu/g	<10cfu/g
Escherichia Coli	Not detected	Not detected
Conclusion	The sample conforms to the Specifications.

Usage

Aniracetam is a γ-lactam-based drug designed to improve brain function.

Aniracetam primarily acts on the nervous system, capable of crossing the blood-brain barrier and selectively targeting the brain. It enhances the metabolism of neurotransmitters, promotes the metabolism of 5-hydroxytryptamine, and effectively shortens selective reaction times. By doing so, it promotes and enhances memory function, improves intelligence, and has neuroprotective effects. Aniracetam also modulates the function of synaptic AMPA receptors and nicotinic acetylcholine receptors (nAChRs), contributing to its neuroprotective and nootropic properties.

Aniracetam is clinically used to treat mild to moderate vascular dementia and Alzheimer's disease, which are associated with learning, memory, and cognitive dysfunction. It is also used to improve memory function after stroke, benign memory disorders in middle-aged and elderly individuals, and developmental delays in children. Animal studies have shown that Aniracetam improves memory reproduction in normal rats and counteracts memory impairment caused by hypoxia.

*Products under the patent are only for R&D use